Thyrocare Technologies shares jump over 7% on robust Q2 results and bonus issue announcement

Shares of Thyrocare Technologies, one of India’s leading pathology laboratory companies, soared over 7% on Wednesday morning. The company announced robust results for Q2 FY26 and made corporate action announcements.

The company delivered a robust performance in Q2FY26 with consolidated revenue of ₹216.53 crore, registering a strong 22% year-on-year growth, led by continued momentum in the Pathology segment, which grew 24% YoY.

On the operational front, the company’s EBITDA jumped 49% to ₹75 crore. Meanwhile, the EBITDA margin stood at 33% for the quarter. The company continues to maintain a healthy balance sheet, remaining debt-free on a consolidated basis and holding net cash and short-term investments exceeding ₹190 crore.

On the bottom line front, the net profit jumped 82% to ₹47.9 crore, up from ₹26 crore in Q2FY25. In addition, the company also announced an interim dividend of ₹7 per share and a bonus issue of 2:1

Commenting on the robust results, MD & CEO Rahul Guha said, “We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare, coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India”

Thyrocare Technologies Limited is India's first and foremost advanced, fully automated laboratory chain with a strong presence PAN India. Thyrocare focuses on providing quality and affordable diagnostic services to laboratories and hospitals.